TOKYO, Jun 15 (Pulse News Wire) – Susmed,inc. (4263.T) announced today that it has achieved a milestone in its joint research and development agreement with Kissei Pharmaceutical Co., Ltd.
Related to treatment apps for otolaryngology. The milestone was reached due to the initiation of clinical trials for an ear ringing treatment app developed jointly by both companies. As per the agreement, SUSMED expects to receive a payment of ¥240 million as part of the development milestones outlined in the contract.
This milestone achievement will be recognized as revenue in the fourth quarter of the fiscal year ending June 2026. The agreement was initially disclosed on November 09, 2022, and the clinical trial for the ear ringing treatment app began on May 07, 2022. The milestone payments are significant indicators of progress in the ongoing collaboration aimed at advancing medical applications in otolaryngological treatments.
🟡 Confidence: Standard AI-translated content.